Till Agnes, Rózsai Barnabás, Kovács Nóra, Storcz Judit, Somogyvári Ferenc, Deák Judit, Ertl Tibor, Decsi Tamás
Pécs Tudományegyetem, Orvos- es Egészségtudományi Centrum, Altalános Orvostudományi Kar, Gyermekklinika, Pécs.
Orv Hetil. 2006 Apr 2;147(13):609-12.
The authors present the cases of two infants with congenital cytomegalovirus infection, who to the best of the authors' knowledge were the first ones to receive ganciclovir treatment in Hungary. Both infants were treated for symptomatic congenital cytomegalovirus infection affecting the central nervous system. Ganciclovir was given intravenously in two phases, for a total of 4 and 6 weeks, in a daily dose of 5-10 mg/kg. Diagnosis of infection and follow-up of treatment efficacy was based on the quantitative assessment by PCR assay of viral nucleic acid in blood and urine samples. Treatment resulted in substantial reduction of viral copy numbers in both infants' blood and urine samples. Improvement in the biochemical markers of disease activity was accompanied with spectacular improvement of clinical symptoms in the infant with severe liver involvement. Following the treatment viral loads increased in both infant but clinical symptoms did not reoccur. In one patient a considerable improvement of hearing loss was observed. The authors' first results indicate that ganciclovir treatment of neonatal cytomegalovirus infection represents a promising approach in preventing the progression of the disease and in ameliorating the consequences.
作者介绍了两例先天性巨细胞病毒感染婴儿的病例,据作者所知,这是匈牙利首批接受更昔洛韦治疗的婴儿。两名婴儿均因影响中枢神经系统的症状性先天性巨细胞病毒感染而接受治疗。更昔洛韦分两个阶段静脉给药,共4周和6周,每日剂量为5-10mg/kg。感染的诊断和治疗效果的随访基于对血液和尿液样本中病毒核酸的PCR定量检测。治疗使两名婴儿血液和尿液样本中的病毒拷贝数大幅减少。疾病活动生化指标的改善伴随着严重肝脏受累婴儿临床症状的显著改善。治疗后,两名婴儿的病毒载量均有所增加,但临床症状未再次出现。在一名患者中,观察到听力损失有相当大的改善。作者的初步结果表明,更昔洛韦治疗新生儿巨细胞病毒感染是预防疾病进展和改善后果的一种有前景的方法。